BAM
NBIX icon

Barrett Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Barrett Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-120
Closed -$5K – 371
2016
Q1 		$5K Buy
+120
New +$4.76K ﹤0.01% 352

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Barrett Asset Management's NBIX Position: Q2 2016 in Review

Barrett Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2016, closing a stake of 120 shares — an estimated $5K sold.

Barrett Asset Management first reported a position in NBIX in Q1 2016 and held it in 1 quarter. The position peaked at $5K in Q1 2016. 231 funds tracked by Wall St. Rank hold NBIX as of Q2 2016.

  • Barrett Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2016 after selling out during the quarter.
  • Barrett Asset Management sold 120 Neurocrine Biosciences shares in Q2 2016, an estimated $5K.
  • Barrett Asset Management first reported a position in Neurocrine Biosciences in Q1 2016 and held it in 1 quarter.
  • Barrett Asset Management's Neurocrine Biosciences position peaked at $5K in Q1 2016.
  • 231 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2016.

Based on Barrett Asset Management's 13F filing for Q2 2016, filed 18 Jul 2016.